IMS data base

IMS Data Base, Intercontinental Medical Statistics Limited, Middlesex HA55HQ, UK. 

A suitable chemical search program for CAS Registry II files had already been developed by CAS, while the various report programs are modified versions of current awareness report programs we have previously developed. The only major new program we needed was one for searching the biological and reference information contained in the IMS data base. 

The biological data we need to search is contained in an IMS data base, which has a hierarchical structure, as shown in Figure 4. This hierarchical structure allows you to have any number of test areas within a compound, any number of test dates within a test area, any number of test types within a test date, etc. (There is of course more detailed information within each segment of the data base than we have depicted.)... 

Pharmacokinetics Pharmacokinetic profiles are summarized in the table below using morphine as the standard. Data based on IM administration unless otherwise noted. ... 

Shown in Figure 3.42, are plots ofthe Im versus the Re components of AR/R (where R refers in this case to the reflectance) or Nyquist plots, recorded at 7, = 433nm, where the values specified identify the frequencies at which the data were collected. The solid line in this figure represents the best fit to the data based on the equivalent circuit proposed. As predicted by Equation 3.23, a plot of —cocotcp versus to2 was linear (see Figure 3.43 on page 242), yielding for 5 s = 10.9 D cm2 and Q=55.2 (iF cm-2, a value for ks of 4.9 x 103 s 1. 

After eliminating products not meeting the criteria for inclusion, 45 products were in the sample. The drugs on OTA s list also were compared with a drugstore database held by Purdue University (based on IMS data), and compounds with no recorded sales in any of the study years were eliminated. After this round, 41 drugs remained in the sample (see table F-l). 

The IMS capability to simultaneously detect multiple metabolites at a time, even with spatial information, facilitates this emerging technique as an effective tool for biomarker discovery, within surgically resected tissues. In fact, a previous study has shown that IMS can discriminate cancer types (such as primary or nonprimary cancer) based on their molecular signature, and can even predict survival rate among human patients [77]. For this kind of purpose, it is necessary to utilize statistical analyses to extract useful information from enormous IMS data sets. The MS of tissues gives an extremely complex spectrum with hundreds of to a thousand peaks obtained from a single data point, and... 

The first non-peptide oxytocin antagonists, based on a spiropiperidine template, were described by Merck in 1992 [68-70]. The binding affinity data for key compounds from this series are summarised in Table 7.2. The initial screening hit, L-342,643, (23), had modest (4/iM) affinity for rat uterine oxytocin receptors and very little vasopressin selectivity [71]. A structure activity relationship (SAR) study was carried out around this template, focussing on the toluenesulphonamide group. This work led to the identification of bulky lipophilic substitution as key to improved oxytocin potency, while the introduction of a carboxylic acid group led to improved... 

Predictions based on the model have been compared to observed time courses for lung, liver, and skeletal americium burden in dogs that inhaled americium oxide (Mewhinney and Griffith 1983). Data on lung retention for four humans who accidentally inhaled americium were also compared to model predictions. The empirical observations fell within predicted retention patterns for particle sizes (AMAD) 0.5 and 1.8 im (Mewhinney and Griffith 1983). 

Data from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. Washington, DC American Psychiatric Association, 2000 429-484 Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders Recommendations from the British Society for Psychopharmacology. J Psychopharmacology 2005 19 567-596 and Katon WJ. Panic disorder. N EnglJ Med 20062554 2560-2567. 

---